- E-postkimberley.hatfield@uib.no
- BesøksadresseHaukeland universitetssykehus, Laboratoriebygget5009 Bergen
- PostadressePostboks 78045020 Bergen
Prosjektet undersøker effekten av ulike medikamenter som blokkerer sentrale metabolske signalveier i akutt myeloid leukemi (AML). Prosjektet har som mål å karakterisere ulike metabolske signalveier i leukemiceller, samt autofagi, og studere hvordan dette bidrar til kjemoresistens i AML. Prosjektet er støttet av midler fra Bergens forskningsstiftelse.
- (2023). Pretransplant systemic metabolic profiles in allogeneic hematopoietic stem cell transplant recipients - identification of patient subsets with increased transplant-related mortality. Transplantation and Cellular Therapy (TCT). 375.e1-375.e14.
- (2022). Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients. Cancers. 21 sider.
- (2022). NPM1-mutated patient-derived AML cells are more vulnerable to rac1 inhibition. Biomedicines. 16 sider.
- (2022). MicroRNA serum profiles and chronic graft-versus-host disease. Blood Advances. 5295-5306.
- (2022). Heterogeneity of patient-derived acute myeloid leukemia cells subjected to SYK in vitro inhibition. International Journal of Molecular Sciences. 21 sider.
- (2022). Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. Biomolecules.
- (2021). Effects of the autophagy‐inhibiting agent chloroquine on acute myeloid leukemia cells; characterization of patient heterogeneity. Journal of Personalized Medicine. 1-23.
- (2020). The PI3K-AKT-MTOR signaling pathway in human acute myeloid leukemia (AML) cells. International Journal of Molecular Sciences. 1-22.
- (2020). Targeting cellular metabolism in acute myeloid leukemia and the role of patient heterogeneity. Cells. 1-26.
- (2019). Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. Cells.
2016-2020: Metabolic phenotypes of leukemia cells.